Crosstalk between cancer and haemostasis

2012 ◽  
Vol 32 (02) ◽  
pp. 95-104 ◽  
Author(s):  
C. Bokemeyer ◽  
F. Langer
Keyword(s):  
Cancer Progression ◽  
Tumour Progression ◽  
Modern Concept ◽  
Anti Cancer ◽  
Haematogenous Metastasis ◽  
Triangular Network ◽  
Cell Dissemination ◽  
Patient Subgroups ◽  
Tumour Cell Dissemination

SummaryCancer is characterized by bidirectional interrelations between tumour progression, coagulation activation, and inflammation. Tissue factor (TF), the principal initiator of the coagulation protease cascade, is centrally positioned in this complex triangular network due to its pleiotropic effects in haemostasis, angiogenesis, and haematogenous metastasis. While formation of macroscopic thrombi is the correlate of cancer-associated venous thromboembolism (VTE), a major healthcare burden in clinical haematology and oncology, microvascular thrombosis appears to be critically important to blood-borne tumour cell dissemination. In this regard, expression of TF in malignant tissues as well as shedding of TFbearing microparticles into the circulation are thought to be regulated by defined genetic events relevant to pathological cancer progression, thus directly linking Trousseau’s syndrome to molecular tumourigenesis.Because pharmacological inhibition of the TF pathway in selective tumour types and patient subgroups would be in line with the modern concept of individualized, targeted anti-cancer therapy, this review will focus on the role of TF in tumour biology and cancer-associated VTE.

Acid ceramidase, a double-edged sword in cancer aggression: A minireview

2020 ◽  
Vol 20 ◽  
Author(s):  
Helen Shiphrah Vethakanraj ◽  
Niveditha Chandrasekaran ◽  
Ashok Kumar Sekar
Keyword(s):  
Cell Fate ◽  
Cancer Progression ◽  
Potential Role ◽  
Tumour Progression ◽  
Acid Ceramidase ◽  
The Core ◽  
The Past ◽  
Sphingosine 1 Phosphate ◽  
Key Enzyme

: Acid ceramidase (AC), the key enzyme of the ceramide metabolic pathway hydrolyzes pro-apoptotic ceramide to sphingosine, which by the action of sphingosine-1-kinase is metabolized to mitogenic sphingosine-1-phosphate. The intracellular level of AC determines ceramide/sphingosine-1-phosphate rheostat which in turn decides the cell fate. The upregulated AC expression during cancerous condition acts as a “double-edged sword” by converting pro-apoptotic ceramide to anti-apoptotic sphingosine-1-phosphate, wherein on one end, the level of ceramide is decreased and on the other end, the level of sphingosine-1-phosphate is increased, thus altogether aggravating the cancer progression. In addition, cancer cells with upregulated AC expression exhibited increased cell proliferation, metastasis, chemoresistance, radioresistance and numerous strategies were developed in the past to effectively target the enzyme. Gene silencing and pharmacological inhibition of AC sensitized the resistant cells to chemo/radiotherapy thereby promoting cell death. The core objective of this review is to explore AC mediated tumour progression and the potential role of AC inhibitors in various cancer cell lines/models.

Role of MicroRNAs in Colon Cancer Progression and Metastasis

2020 ◽  
Vol 20 ◽  
Author(s):  
Shruthi Sanjitha Sampath ◽  
Sivaramakrishnan Venkatabalsubramanian ◽  
Satish Ramalingam
Keyword(s):  
Colon Cancer ◽  
Cancer Progression ◽  
Target Genes ◽  
Tumour Progression ◽  
Intestinal Barrier ◽  
Colon Cancer Progression ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Novel Therapeutic Strategies

: MicroRNAs regulate gene expression at the posttranscriptional level by binding to the mRNA of their target genes. The dysfunction of miRNAs is strongly associated with the inflammation of the colon. Besides, some microRNAs are shown to suppress tumours while others promote tumour progression and metastasis. Inflammatory bowel diseases include Crohn’s disease and Ulcerative colitis which increase the risk factor for inflammation-associated colon cancer. MicroRNAs are shown to be involved in gastrointestinal pathologies, by targeting the transcripts encoding proteins of the intestinal barrier and their regulators that are associated with inflammation and colon cancer. Detection of these microRNAs in the blood, serum, tissues, faecal matter, etc will enable us to use these microRNAs as biomarkers for early detection of the associated malignancies and design novel therapeutic strategies to overcome the same. Information on MicroRNAs can be applied for the development of targeted therapies against inflammation-mediated colon cancer.

Role of protein S-Glutathionylation in cancer progression and development of resistance to anti-cancer drugs

2021 ◽  
Vol 704 ◽  
pp. 108890
Author(s):  
Debojyoti Pal ◽  
Archita Rai ◽  
Rahul Checker ◽  
R.S. Patwardhan ◽  
Babita Singh ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Protein S ◽  
Cancer Drugs ◽  
Development Of Resistance ◽  
Anti Cancer

The role of microvesicles in cancer progression and drug resistance

2013 ◽  
Vol 41 (1) ◽  
pp. 293-298 ◽  
Author(s):  
Samireh Jorfi ◽  
Jameel M. Inal
Keyword(s):  
Drug Resistance ◽  
Multidrug Resistance ◽  
Cancer Progression ◽  
Chemotherapeutic Agents ◽  
Malignant Cells ◽  
Intercellular Transport ◽  
Wide Range ◽  
Anti Cancer ◽  
Mdr Multidrug Resistance

Microvesicles are shed constitutively, or upon activation, from both normal and malignant cells. The process is dependent on an increase in cytosolic Ca2+, which activates different enzymes, resulting in depolymerization of the actin cytoskeleton and release of the vesicles. Drug resistance can be defined as the ability of cancer cells to survive exposure to a wide range of anti-cancer drugs, and anti-tumour chemotherapeutic treatments are often impaired by innate or acquired MDR (multidrug resistance). Microvesicles released upon chemotherapeutic agents prevent the drugs from reaching their targets and also mediate intercellular transport of MDR proteins.

scholarly journals The Role of SATB1 in Tumour Progression and Metastasis

2019 ◽  
Vol 20 (17) ◽  
pp. 4156 ◽  
Author(s):  
Glatzel-Plucińska ◽  
Piotrowska ◽  
Dzięgiel ◽  
Podhorska-Okołów
Keyword(s):  
Cancer Progression ◽  
Poor Prognosis ◽  
Tumour Progression ◽  
Prognostic Significance ◽  
Distant Metastases ◽  
Mesenchymal Transition ◽  
Epithelial Cancers ◽  
Multistep Process ◽  
Satb1 Expression

Carcinogenesis is a long-drawn, multistep process, in which metastatic spread is an unequivocal hallmark of a poor prognosis. The progression and dissemination of epithelial cancers is commonly thought to rely on the epidermal-mesenchymal transition (EMT) process. During EMT, epithelial cells lose their junctions and apical-basal polarity, and they acquire a mesenchymal phenotype with its migratory and invasive capabilities. One of the proteins involved in cancer progression and EMT may be SATB1 (Special AT-Rich Binding Protein 1)—a chromatin organiser and a global transcriptional regulator. SATB1 organizes chromatin into spatial loops, providing a “docking site” necessary for the binding of further transcription factors and chromatin modifying enzymes. SATB1 has the ability to regulate whole sets of genes, even those located on distant chromosomes. SATB1 was found to be overexpressed in numerous malignancies, including lymphomas, breast, colorectal, prostate, liver, bladder and ovarian cancers. In the solid tumours, an elevated SATB1 level was observed to be associated with an aggressive phenotype, presence of lymph node, distant metastases, and a poor prognosis. In this review, we briefly describe the prognostic significance of SATB1 expression in most common human cancers, and analyse its impact on EMT and metastasis.

scholarly journals N-cadherin antagonists as oncology therapeutics

2015 ◽  
Vol 370 (1661) ◽  
pp. 20140039 ◽  
Author(s):  
Orest W. Blaschuk
Keyword(s):  
Cell Adhesion ◽  
Cancer Progression ◽  
Structural Integrity ◽  
Cancer Therapies ◽  
Transmembrane Glycoprotein ◽  
Anti Cancer ◽  
Different Types ◽  
Poorly Differentiated ◽  
Novel Strategy

The cell adhesion molecule (CAM), N-cadherin, has emerged as an important oncology therapeutic target. N-cadherin is a transmembrane glycoprotein mediating the formation and structural integrity of blood vessels. Its expression has also been documented in numerous types of poorly differentiated tumours. This CAM is involved in regulating the proliferation, survival, invasiveness and metastasis of cancer cells. Disruption of N-cadherin homophilic intercellular interactions using peptide or small molecule antagonists is a promising novel strategy for anti-cancer therapies. This review discusses: the discovery of N-cadherin, the mechanism by which N-cadherin promotes cell adhesion, the role of N-cadherin in blood vessel formation and maintenance, participation of N-cadherin in cancer progression, the different types of N-cadherin antagonists and the use of N-cadherin antagonists as anti-cancer drugs.

scholarly journals The role of NDRG1 in the pathology and potential treatment of human cancers

2013 ◽  
Vol 66 (11) ◽  
pp. 911-917 ◽  
Author(s):  
Dong-Hun Bae ◽  
Patric J Jansson ◽  
Michael L Huang ◽  
Zaklina Kovacevic ◽  
Danuta Kalinowski ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Anticancer Agents ◽  
Tumour Progression ◽  
Antitumour Activity ◽  
Primary Tumour ◽  
Normal Tissues ◽  
Human Cancers ◽  
Physiological Processes ◽  
Cancer Pathology

N-myc downstream regulated gene 1 (NDRG1) has been well characterised to act as a metastatic suppressor in a number of human cancers. It has also been implicated to have a significant function in a number of physiological processes such as cellular differentiation and cell cycle. In this review, we discuss the role of NDRG1 in cancer pathology. NDRG1 was observed to be downregulated in the majority of cancers. Moreover, the expression of NDRG1 was found to be significantly lower in neoplastic tissues as compared with normal tissues. The most important function of NDRG1 in inhibiting tumour progression is associated with its ability to suppress metastasis. However, it has also been shown to have important effects on other stages of cancer progression (primary tumour growth and angiogenesis). Recently, novel iron chelators with selective antitumour activity (ie, Dp44mT, DpC) were shown to upregulate NDRG1 in cancer cells. Moreover, Dp44mT showed its antimetastatic potential only in cells expressing NDRG1, making this protein an important therapeutic target for cancer chemotherapy. This observation has led to increased interest in the examination of these novel anticancer agents.

scholarly journals H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 485 ◽  
Author(s):  
Marta Hałasa ◽  
Anna Wawruszak ◽  
Alicja Przybyszewska ◽  
Anna Jaruga ◽  
Małgorzata Guz ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Posttranslational Modifications ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Future Perspectives ◽  
Free Survival ◽  
Histone 3 ◽  
Anti Cancer ◽  
Disease Free

Acetylation and deacetylation are posttranslational modifications (PTMs) which affect the regulation of chromatin structure and its remodeling. Acetylation of histone 3 at lysine placed on position 18 (H3K18Ac) plays an important role in driving progression of many types of cancer, including breast, colon, lung, hepatocellular, pancreatic, prostate, and thyroid cancer. The aim of this review is to analyze and discuss the newest findings regarding the role of H3K18Ac and acetylation of other histones in carcinogenesis. We summarize the level of H3K18Ac in different cancer cell lines and analyze its association with patients’ outcomes, including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Finally, we describe future perspectives of cancer therapeutic strategies based on H3K18 modifications.

The Role of PI3K and Wntsignaling Pathways and CSC Markers in Melanoma (B16F10) Therapy

2021 ◽  
Author(s):  
marjan hajimoradi javarsiani ◽  
javad sajedianfard ◽  
Shagayegh Haghjooy Javanmard ◽  
Micol Eleonora Fiori
Keyword(s):  
Cancer Progression ◽  
Therapeutic Agent ◽  
B16f10 Melanoma ◽  
Melanoma Cancer ◽  
Anti Cancer ◽  
Melanoma B16f10 ◽  
The Subject ◽  
Cell Growth And Proliferation

Abstract Background Metformin has been the subject of recent studies aimed at the treatment of melanoma cancer. In this study, the anti-cancer effects of metformin, an antidiabetic drug, was investigated in-vitrousing the B16F10 melanoma cell line. Methods Melanoma cells were treated for 24 h with various concentrations of metformin, alone or incombination withdacarbazine. The effects of these two treatment agents on cell viability were evaluated by MTT assay. In addition, stemness and the activation of specific signaling pathways were evaluated by FACS and immunoblotting. Results Metformin induced β-catenin phosphorylation and decreasedmTOR and PARP expressions. Also, a normal dose of metformin was found toreducethe phosphorylation levels of4E-BP1, AKT, and S6rp.In this study, we evaluated the potential of metformin as a therapeutic agent against CSCs in the adjuvant setting. Conclusion Our data indicate that some transcriptional regulators and proteins in the above-mentioned pathwayswere associated with cancer progression and inhibited by adjuvant chemotherapy with metformin.Metformin significantly inhibited cell growth and proliferation pathways, including Wnt and PI3K/AKT/mTOR. These findings show the potential of metformin in cancer treatment.

scholarly journals Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease

2019 ◽  
Vol 20 (10) ◽  
pp. 2519 ◽  
Author(s):  
Sheetal Parida ◽  
Sumit Siddharth ◽  
Dipali Sharma
Keyword(s):  
Cancer Progression ◽  
Protective Role ◽  
The Body ◽  
Biological Functions ◽  
Anti Cancer ◽  
Guardian Angel ◽  
Health And Disease ◽  
Obesity And Cancer ◽  
Multiple Signaling

Adiponectin is one of the most important adipocytokines secreted by adipocytes and is called a “guardian angel adipocytokine” owing to its unique biological functions. Adiponectin inversely correlates with body fat mass and visceral adiposity. Identified independently by four different research groups, adiponectin has multiple names; Acrp30, apM1, GBP28, and AdipoQ. Adiponectin mediates its biological functions via three known receptors, AdipoR1, AdipoR2, and T-cadherin, which are distributed throughout the body. Biological functions of adiponectin are multifold ranging from anti-diabetic, anti-atherogenic, anti-inflammatory to anti-cancer. Lower adiponectin levels have been associated with metabolic syndrome, type 2 diabetes, insulin resistance, cardiovascular diseases, and hypertension. A plethora of experimental evidence supports the role of obesity and increased adiposity in multiple cancers including breast, liver, pancreatic, prostrate, ovarian, and colorectal cancers. Obesity mediates its effect on cancer progression via dysregulation of adipocytokines including increased production of oncogenic adipokine leptin along with decreased production of adiponectin. Multiple studies have shown the protective role of adiponectin in obesity-associated diseases and cancer. Adiponectin modulates multiple signaling pathways to exert its physiological and protective functions. Many studies over the years have shown the beneficial effect of adiponectin in cancer regression and put forth various innovative ways to increase adiponectin levels.

Sign in / Sign up

Export Citation Format

Share Document